ArticleDiscover oncology2025
A rare case of HER2-positive pure metaplastic squamous cell carcinoma of the breast.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary squamous cell carcinoma of the breast (PSCCB) is a rare form of metaplastic breast carcinoma (MpBC), constituting approximately 0.1% of all invasive breast cancers. It is characterized by unique morphological and clinical features, exhibiting a high degree of invasiveness and a poor prognosis. Most molecular subtypes are negative for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), while HER2-positive PSCCB is even rarer, accounting for approximately 4-22% of cases. Accurate histological diagnosis is crucial for effective management.Currently, there is limited research on neoadjuvant chemotherapy combined with targeted therapy for HER2-positive PSCCB, and standardized treatment protocols have yet to be established. We report a case of pure HER2-positive PSCCB with the aim of gaining experience in the treatment of HER2-positive PSCCB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.